retatrutide clinical trials phase Today, we shared new data from two 3 of retatrutide, our investigational triple agonist. Learn more at our link in bio Lilly's 'triple G' agonist triumphs

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al

This history matters because it establishes a pattern of marketing that outpaces the science

Early research suggests retatrutide may be one of the most powerful weight-loss medications studied so far

Obesity is explicitly listed as a Phase 1 program in public disclosures and is not a primary commercial focus for the drug

Custom Medication Plan Based on your needs, we prescribe Semaglutide or Tirzepatide, with precise dosing adjustments for optimal fat loss and minimal side effects

For patients with thyroid disease, particular attention should be paid to thyroid function monitoring, as weight changes may influence thyroid hormone requirements